Acutus Medical (AFIB) Gets a Hold Rating from Goldman Sachs

In a report released today, Amit Hazan from Goldman Sachs maintained a Hold rating on Acutus Medical (AFIBResearch Report), with a price target of $1.00. The company’s shares closed last Wednesday at $0.92, close to its 52-week low of $0.90.

According to, Hazan is a 4-star analyst with an average return of 8.2% and a 58.4% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Baxter International, Intuitive Surgical, and Outset Medical.

Acutus Medical has an analyst consensus of Hold, with a price target consensus of $1.50, a 61.6% upside from current levels. In a report issued on March 30, BTIG also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

Acutus Medical’s market cap is currently $25.97M and has a P/E ratio of -0.22.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. Its operates in United States and Europe with majority of the revenue generating from Europe.

Read More on AFIB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More